Transradial Access Devices Market Size & Share 2025 - 2034

Transradial Access Devices Market Size

The global transradial access devices market was valued at USD 2.4 billion in 2024 and is projected to exhibit 7.7% CAGR from 2025-2034. The revenue growth in the market is being driven by the rising adoption of interventional procedures and the increasing prevalence of cardiovascular diseases.

The demand for transradial access devices is growing with the rising burden of CVDs due to the increasing preference for these devices in minimally invasive procedures like angiography and angioplasty. Along with reduced bleeding risk, quicker recovery, and shorter hospital stays, transradial access offers several advantages. According to WHO 2021 factsheet, CVDs are responsible for more than 32% of deaths worldwide which is over 17.9 million deaths each year which stresses the need for efficient and patient-friendly treatments. The increasing prevalence of cardiovascular diseases is contributing to the expansion of the market for sophisticated transradial access instruments designed to improve procedural results and the overall experience for patients.
 

In addition, the growing use of interventional techniques involving approach via radial artery is positively influencing the market for transradial access devices. In comparison to femoral access, radial artery access is associated with fewer complications, better patient comfort, and quicker mobilization. These changes are supported by the widespread use of the radial-first approach in catheterization labs owing to demonstrable clinical safety and enhanced efficiency.
 

Transradial access devices are specific implantable medical tools that allow vascular access at the wrist using the radial artery for diagnostic or therapeutic procedures like coronary angiography and percutaneous coronary interventions. These devices consist of catheters, sheaths, guidewires, and hemostasis bands, which provide a less invasive method that diminishes complications, improves patient satisfaction, and allows for faster recovery than conventional femoral access techniques.

Transradial Access Devices Market Trends

• The adoption of Hydrophilic coated catheters is increasing across cardiac procedures. Hydrophilic coated catheters have a particular coating that minimizes the risk of injury to vascular structures during their insertion and withdrawal due to decreased friction. The hydrophilic surface is well able to traverse blood vessels, particularly in difficult anatomical arrangements as it increases smoother and more efficient navigation. This technology is especially useful in reduction of patient discomfort and complicating events such as artery spasm.
   
• Moreover, modern hemostasis bands that come with adjustable pressure settings is enabling healthcare providers to optimally constrain the bleeding from the radial artery without fully occluding blood flow. This feature is helping to reduce the risk of certain complications such as radial artery occlusion which require more time to heal. In addition, enhanced ergonomics across devices is promoting patient recovery from procedures through improving the comfort.
   
• The introduction of Cordis’ RAILWAY Access System, and Terumo’s Glidesheath Slender, that have slender sheaths and sheathless access systems, has enabled the use of greater sized catheters to be used on smaller radial arteries. This advancements have resulted into the reduced risk of trauma and radial artery occlusion.
   
• Further, owing to growth in robotic assisted surgery, the vendors are focusing towards offering robotic-assisted PCI platforms to make their devices more compatible across robotic assisted surgeries.
   

Trump Administration Tariffs

• The cost of transradial access devices are likely to increase as a direct effect of imposing tariffs on imports specifically from China. The increased costs will be passed on to the consumer market resulting in higher price of transradial access devices. Manufacturers may also stop selling some vital devices altogether due to their inability to control the costs of essential components required to assemble these devices.
   
• Companies with foreign subsidiaries that fully outsource their manufacturing activities will be impacted the most. On the other hand, companies such as Becton Dickinson, which manufactures smaller share of its product overseas would be comparatively less disrupted. Smaller players are likely to rethink relocating production to the U.S. to avoid tariffs or may diversify their supply chain of components to multiple countries.
   
• Healthcare facilities will have to deal with budget constraints dealing with increasing device procurement costs which may hinder patient access to care.
   
• Investments in the medical devices sector may be put at risk due to unpredictable costs and availability of supplies. Increased costs of operations might limit funding availabilities for research and developments of new technologies, including new devices for transradial access.
   

Transradial Access Devices Market Analysis

Based on product, the market is segmented into catheters, guidewires, sheath and sheath introducers, and accessories. The catheters segment dominates the market with a share of 49.4% in 2024.
 

• Catheters play a critical role in diagnostic angiograms and interventional procedures like percutaneous coronary interventions. Their usefulness in performing these procedures is due to their ability to advance through complex vascular systems and administer contrast materials, therapeutic devices, or guidewires. Owing to global increase in the prevalence of cardiovascular diseases, there is an increasing need for catheter-based diagnostic and therapeutic interventions.
   
• According to the WHO 2021 factsheet, out of a total of 17 million premature deaths (below the age of 70) resulting from noncommunicable diseases, 38% were attributed to cardiovascular diseases (CVDs). As a result, the demand for cardiac surgeries involving transradial access is increasing, further driving the use of catheters.
   
• Further, technological advances in the catheter materials and designs, such as the use of led catheters with hydrophilic coatings, specialized designs for radial access, and other advanced torque control catheters, have resulted to improve procedural success rates and patient outcomes significantly. Such advanced features have led to a wider acceptance of transradial catheters among physicians.
   

Based on application, the transradial access devices market is segmented into drug administration, fluid and nutrition administration, blood transfusion, diagnostics and testing, and other applications. The drug administration segment dominated the market with a share of 36.8% in 2024 and is expected to value at USD 1.8 billion in 2034.
 

• Transradial access devices are used to deliver critical medications like thrombolytics and vasodilators during cardiovascular procedures. This less invasive technique augments pharmacological treatment by allowing direct drug delivery to the site of action, thereby achieving better outcomes and shorter recovery periods. This methodical approach is critical, especially with the increasing prevalence of cardiovascular diseases. This contributes to a dominating share of the segment.
   
• Moreover, the transradial approach is gaining popularity for drug delivery in clinical oncology, where the precise localization of chemotherapeutic agent administration is essential.
   
• Further, each year, significant number of both diagnostic and interventional cardiovascular surgeries are performed through a transradial approach. For example, as per the 2023 study published by National Library of Medicine, PCI has emerged as one of the most common CAD treatment procedures globally, with over 2 million procedures performed annually globally. These surgeries almost always require some form of intra-arterial infusion of medication, making drug administration application widespread.
   

Learn more about the key segments shaping this market

Download Free PDF

 

Based on end use, the transradial access devices market is segmented into hospital & clinics, ambulatory surgical centers, and other end users. The hospital & clinics segment dominated the market with a share of 42.2% in 2024.
 

• Transradial access devices are commonly employed in conjunction with advanced cardiovascular and interventional procedures in clinics and hospitals. These facilities have highly trained medical personnel and modern infrastructure, which is why they are preferred for procedures such as coronary angioplasty and stenting. With an increasing number of patients undergoing such procedures, this segment continues to dominate.
   
• Moreover, hospitals provide all-inclusive care inclusive of pre-procedural preparation, real-time imaging done during the procedure, and post-procedure monitoring, all of which are important for transradial interventions. The availability of such specialized care garners better safety and outcomes for patients, motivating increased use of transradial access devices in these centers.
   
• This trend is further supported by the rising developments in hospital infrastructure across the globe, fueled by the rising population and their increasing healthcare service needs. For instance, as per the International Journal of Health Planning and Management, there is also a growing demand for care as chronic cardiovascular diseases develop, with the UK projecting 40% growth in hospital care requirements in the coming decades, particularly for elderly patients.
   

• In 2024, the U.S. led the North America market, generating a revenue of about USD 881.8 million.
   
• The rising prevalence of cardiovascular diseases (CVDs) in the U.S. is a notable factor supporting the transradial access devices market.  For instance, as per the 2024 article from CDC, one person dies every 33 seconds from cardiovascular disease.
   
• Owing to high burden of morbidity and mortality associated with CVDs, advanced interventional procedures that employ transradial access devices are on the rise. Particularly, coronary artery diseases is increasing the need for less invasive procedures owing to the reduced complications and quicker recovery associated with transradial procedures.
   
• Moreover, the U.S. observes a significant volume of cardiac catheterizations and PCI procedures every year. According to the 2023 study published on NCBI, the U.S. performs about 1 million cardiac catheterization procedures every year. A rising fraction of these procedures employ transradial access, fueled by guidelines and operator preference, which further supports market growth.
   
• Further, Medicare and private health insurers offer optimum reimbursement for transradial access procedures in the U.S., prompting hospitals to implement efficient outpatient percutaneous coronary intervention programs utilizing radial access.
   

Europe: UK is set to see a robust expansion in transradial access devices market from 2025 to 2034.
 

• In UK, government is increasingly promoting the use of less invasive cardiovascular procedures to further decrease patient recovery time, the duration of hospital stays, and healthcare expenditure. For instance, evaluation and adoption of newer techniques and devices including radial access devices in UK are being facilitated through organizations such as NICE and NHS Innovation Accelerator.
   
• Moreover, transradial access devices are gaining preference as they offer superior recovery benefits to patients in comparison to traditional femoral access. With the changes in traditional approaches towards more minimally invasive techniques, the market is being boosted.
   
• Also, in UK, the National Health Service (NHS) along with other healthcare providers have been focusing on improving the quality of outcomes in the management of cardiovascular disease, particularly for the patients who undergo interventional procedures. Fellowship funding and healthcare policies that support the application of sophisticated medical technologies such as transradial access devices are facilitating to broaden their deployment across hospitals and clinics.
   

Asia Pacific: Japan's transradial access devices market is set for lucrative growth from 2024 to 2034.
 

• The increasing geriatric population in Japan is one of the key reason boosting the demand for cardiovascular care, including care that uses transradial access devices. According to the World Bank Group, about 30% of population in Japan is aged 65 and above, contributing to high risk of age-related cardiovascular diseases in the country.
   
• Moreover, presence of advanced healthcare infrastructure and medical technology in Japan also eases the access of patients towards complex medical procedures involving transradial access. The Japanese interventional cardiologists were early adopters of the radial-first approaches.
   
• According to the Japanese study published by The Lancet Group in November 2022, the adoption of transradial access procedures in Japan for percutaneous coronary intervention is estimated to be around 70%. Such as high adoption of transradial access across PCI procedures ensures steady demand for transradial access devices in Japan.
   

Middle East and Africa: Saudi Arabia's transradial access devices market is expected to witness substantial growth during the forecast period.
 

• Saudi Vision 2030 is encouraging advanced surgical interventions as non-invasive and modern therapeutic techniques are being integrated into new hospitals' surgical and catheterization facilities.
   
• Moreover, according to a WHO in 2023, cardiovascular diseases were among the leading causes of mortality in Saudi Arabia, with ischaemic heart disease accounting for over 45.7 deaths per 100,000 population. As a result, the increase in cardiac disorders are increasing the need for percutaneous coronary interventions, as well as transfemoral catheterization. This is driving the revenue growth in Saudi Arabia.
   

Transradial Access Devices Market Share

The market has presence of both global and local companies competing to meet the demand for more minimally invasive cardiovascular procedures which require advanced devices to provide better outcomes for patients. Terumo, Becton, Dickinson and Company, Boston Scientific, Medtronic, and Merit Medical Systems are among the key players in the market that contributes to about 70% market share.
 

The use of sophisticated technology and providing tailored care towards hospitals, diagnostic centers, and ambulatory care centers are some of the dominant factors that shape competition along with regulatory compliances. In developing countries, pre-existing global contenders face competition when trying to implant cost-effective advanced transradial access devices. Local manufacturers take this opportunity and compete on price which drives the established players to lower the prices while maintaining device efficacy, safety, and regulatory standards.
 

Transradial Access Devices Market Companies

Some of the eminent market participants operating in the transradial access devices industry include:

• Alvimedica
• Ameco Medical Industries
• AngioDynamics
• Becton Dickinson and Company
• Boston Scientific
• Cardinal Health
• Edward Lifesciences
• ICU Medical
• InnoMedica
• Medtronic
• Merit Medical System
• NIPRO Medical
• Oscor
• Palex Medical
• Teleflex
• Terumo
   
• Terumo is well known for being the first to develop transradial access procedures and also offers a comprehensive range of radial particular sheaths, catheters, and guidewires. Their focus on clinician training and patient safety has strengthened their leadership in this field.
   
• BD focuses on innovation-driven acquisitions, which has strengthened their industry position. In addition, BD has an extensive portfolio of vascular access devices which features auto-disable and safety-engineered elements.
   
• Boston Scientific offers novel therapies for interventional cardiology, which include transradial access devices. Their substantial R&D investment allows new products to be developed improving the efficiency of the procedure and outcomes of the patients.
   

Transradial Access Devices Industry News:

• In May 2024, Teleflex announced the launch of the Arrow EZ-IO Intraosseous Access Procedure Tray. Everything necessary for the IO access procedure is included in this single-dose, sterile tray, allowing clinicians to work more efficiently.
   

The new Arrow EZ-IO Procedure Tray contains the first battery powered driver that the FDA has cleared for sterile, single use, and rigid battery powered drivers that can be employed in the operating rooms or any other area in the hospital which necessitates the use of a sterile field barrier.
 

• In October 2023, Merit Medical Systems announced that it has broadened the Maestro microcatheter line by adding a new longer length for radial embolization procedures. Maestro is also part of the company‘s portfolio of embolotherapy products, which consists of Embosphere microspheres.
   
• In November 2022, Amneal Pharmaceuticals announced the resubmission to the U.S. Food and Drug Administration (FDA) of its new drug application (NDA) for dihydroergotamine (DHE) prefilled syringe autoinjector. The FDA previously issued a complete response letter due to facility inspection issues, prompting Amneal to transfer production in-house.
   
• In February 2021, Merit Medical Systems announced the launch of the PreludeSYNC EZ Radial Compression Device. This device is designed to enhance radial artery access procedures by providing controlled and precise compression, featuring a unique cinch-style wristband that allows for two-handed placement and clear visibility of the access site. The PreludeSYNC EZ aims to optimize hemostasis following radial artery access, improving patient outcomes and clinician experience in endovascular procedures.
   

The transradial access devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product  

• Catheters
• Guidewires
• Sheath and sheath introducers
• Accessories

Market, By Application

• Drug administration
• Fluid and nutrition administration
• Blood transfusion
• Diagnostics and testing
• Other applications

Market, By End Use  

• Hospitals and clinics
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • South Korea
  • Australia
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE